S Luby1, J Jones, J Horan. 1. Division of Field Epidemiology, Centers for Disease Control and Prevention, Atlanta, Ga 30333.
Abstract
OBJECTIVES: CD4 lymphocyte counts decrease with the duration of human immunodeficiency virus (HIV) infection. We used CD4 counts collected for clinical reasons to evaluate the stage of HIV infection and the epidemiology of recent HIV infections among attendees of South Carolina's public health clinics. METHODS: We measured the CD4 T-lymphocyte counts of persons newly diagnosed with HIV infection April 1989 through June 1990 at South Carolina public health clinics who returned for follow-up. RESULTS: Of 812 newly diagnosed HIV-infected health department patients, 420 (52%) had their CD4 lymphocyte counts measured. Of these 420, 51 (12%) had CD4 counts of < 200, the level below which prophylaxis for pneumocystis pneumonia prolongs survival, and 193 (46%) had CD4 counts of < 500, the level below which zidovudine may prolong disease-free survival. The highest CD4 counts (> or = 900), which are associated with more recent HIV infection, were more common in females. CONCLUSIONS: In South Carolina, almost half of newly reported HIV-infected persons who agreed to CD4 testing at the health department might benefit from immediate drug therapy. Within this population, women may be an emerging risk group that requires specifically directed HIV prevention efforts.
OBJECTIVES:CD4 lymphocyte counts decrease with the duration of human immunodeficiency virus (HIV) infection. We used CD4 counts collected for clinical reasons to evaluate the stage of HIV infection and the epidemiology of recent HIV infections among attendees of South Carolina's public health clinics. METHODS: We measured the CD4 T-lymphocyte counts of persons newly diagnosed with HIV infection April 1989 through June 1990 at South Carolina public health clinics who returned for follow-up. RESULTS: Of 812 newly diagnosed HIV-infected health department patients, 420 (52%) had their CD4 lymphocyte counts measured. Of these 420, 51 (12%) had CD4 counts of < 200, the level below which prophylaxis for pneumocystis pneumonia prolongs survival, and 193 (46%) had CD4 counts of < 500, the level below which zidovudine may prolong disease-free survival. The highest CD4 counts (> or = 900), which are associated with more recent HIV infection, were more common in females. CONCLUSIONS: In South Carolina, almost half of newly reported HIV-infectedpersons who agreed to CD4 testing at the health department might benefit from immediate drug therapy. Within this population, women may be an emerging risk group that requires specifically directed HIV prevention efforts.
Authors: J F Brundage; J G McNeil; R N Miller; L I Gardner; S M Harrison; C Hawkes; D B Craig; R Redfield; D S Burke; C Hawks Journal: J Acquir Immune Defic Syndr (1988) Date: 1990
Authors: F de Wolf; J M Lange; J T Houweling; J W Mulder; J Beemster; P T Schellekens; R A Coutinho; J van der Noordaa; J Goudsmit Journal: AIDS Date: 1989-09 Impact factor: 4.177
Authors: P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch Journal: N Engl J Med Date: 1990-04-05 Impact factor: 91.245
Authors: Ikechukwu U Ogbuanu; Myriam E Torres; Lynda Kettinger; Helmut Albrecht; Wayne A Duffus Journal: Am J Public Health Date: 2007-11-29 Impact factor: 9.308